Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia

NCT00328198 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

86

Enrollment

INDUSTRY

Sponsor class

Conditions

B-Cell Chronic Lymphocytic Leukemia (B-CLL)

Interventions

BIOLOGICAL: Alemtuzumab
BIOLOGICAL: Alemtuzumab

Sponsor

Genzyme, a Sanofi Company

Collaborators

[object Object]